Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California
blank

 

Recent News and Articles on the Keywords: myocardial infarction + first vioxx + vioxx  Related to the article below (Last Update: 7/1/2008)

New Jersey Supreme Court Dismisses Medical Monitoring Suit Filed ...
Business Wire (press release), CA - Jun 4, 2008
The plaintiffs in this suit sought to recover from Merck even though VIOXX has been off the market for almost four years and they do not claim that it ever ...
Source: Google News

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo- … -
DJ Graham, D Campen, R Hui, M Spence, C Cheetham, … - The Lancet, 2005 - Elsevier
... in a large randomised clinical trial (Vioxx Gastrointestinal Outcomes ... until occurrence
of an acute myocardial infarction or death, whichever came first. ...

Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other … -
SP Johnsen, H Larsson, RE Tarone, JK McLaughlin, B … - Archives of Internal Medicine, 2005 - Am Med Assoc
... on an increased risk of myocardial infarction (MI) and ... stimulated by data from the
Vioxx Gastrointestinal Outcomes ... First, data on the risk associated with COX ...

The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly … -
LE Levesque, JM Brophy, B Zhang - Annals of Internal Medicine, 2005 - annals.highwire.org
... Do risks for myocardial infarction (MI) differ among ... potential cardiovascular toxicity
were first raised in 2000 after the Vioxx Gastrointestinal Outcomes ...

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis -
P J?ni, L Nartey, S Reichenbach, R Sterchi, PA … - The Lancet, 2004 - Elsevier
... has been questioned since the Vioxx Gastrointestinal Outcomes ... for the risk of myocardial
infarction and naproxen ... included the year they first became available ...

[CITATION] Non-Steroidal Antiinflammatory Drugs and the Risk of Acute Myocardial Infarction -
S Hernandez-Diaz, C Varas-Lorenzo, LA Garcia … - Basic & Clinical Pharmacology & Toxicology, 2006 - Blackwell Synergy
... The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial investigators. New Engl.
J. Med. ... first myocardial infarction by nonsteroidal anti-inflammatory drugs. ...

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non- … -
J Hippisley-Cox, C Coupland - BMJ, 2005 - pubmedcentral.nih.gov
... In the Vioxx gastrointestinal outcomes research (VIGOR) study, patients taking ... needed
to harm by applying the incidence of first myocardial infarction per 1000 ...

… -2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction -
F Andersohn, S Suissa, E Garbe - Circulation, 2006 - Am Heart Assoc
... Adenomatous Polyp Prevention on Vioxx (APPROVe) trial ... for current use of the
first-generation COX ... and 1.56 elevated risk of myocardial infarction, respectively. ...

Lessons from the withdrawal of rofecoxib: Patients would be safer if drug companies disclosed … -
PA Dieppe, S Ebrahim, RM Martin, P J?ni - BMJ: British Medical Journal, 2004 - pubmedcentral.nih.gov
... One of the first NSAIDs to be heavily ... 2 A subsequent agent was rofecoxib (Vioxx)
produced by Merck ... increase in the risk of myocardial infarction (relative risk ...

Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction -
SE Kimmel, JA Berlin, M Reilly, J Jaskowiak, L … - Annals of Internal Medicine, 2005 - annals.highwire.org
... similar among adults with a first, nonfatal myocardial ... reduce the risk for myocardial
infarction (MI) by ... In the Vioxx Gastrointestinal Outcomes Research (VIGOR ...

… Between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults -
DH Solomon, S Schneeweiss, RJ Glynn, Y Kiyota, R … - Circulation, 2004 - Am Heart Assoc
... the first 90 days of use but not thereafter. (Circulation. 2004;109:2068-2073.)
Key Words: cyclooxygenase inhibitors myocardial infarction aging T he Vioxx and ...

Source: Google Scholar
 
 

Vioxx: myocardial infarction can occur within the first two weeks of use

 
 
A study by investigators at the McGill University Health Centre ( MUHC ) found that a quarter of patients who suffered a myocardial infarction while taking Vioxx ( Rofecoxib ) did so within the first two weeks of taking the drug.

The research, published in the Canadian Medical Association Journal ( CMAJ ),demonstrated that cardiovascular risks from taking Vioxx may occur much earlier than previously believed.

" Our previous study on COX-2 inhibitors, which included Vioxx and Celebrex ( Celecoxib ), evaluated whether there was an increased risk of myocardial infarction while taking these medications; the answer was yes for Vioxx," says Linda Levesque, at McGill University in Montreal and lead author of the new study. " Our current study assessed the pattern of cardiovascular risk in Québec seniors over a three year period, in order to establish the timing of this risk."

Levesque, in collaboration with James Brophy and Bin Zhang discovered that the risk of myocardial infarction from Vioxx is much more acute than previously recognized.

" A quarter of individuals in our study who suffered an acute myocardial infarction did so within two weeks of their first Vioxx prescription," says Levesque.

" The additional cardiovascular risk from Vioxx actually decreased with longer duration of use, suggesting that the period of highest susceptibility for most people taking Vioxx may occur earlier than previously believed," noted Levesque. The study also documents that cardiovascular risk returns to normal within one month of stopping the drug.

Vioxx was voluntarily withdrawn from the market on September 30, 2004 after a study showed it doubled patients' risk of myocardial infarction and strokes after 18 months of use.

The MUHC study is the first to specifically address the question of the timing of cardiovascular risk associated with COX-2 inhibitors.

Source: McGill University, 2006
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; Nedws9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page